News
Lilly pays AstraZeneca $100m as Alzheimer's drug enters phas...
AstraZeneca and Eli Lilly are to continue with a pivotal phase 2/3 study of a key pipeline drug, AZD3293 for early Alzheimer's disease, after interim safety data boosted confidence in the d